Non-Motor Parkinson's Disease Study Group

K. Ray Chaudhuri Per Odin Annette Schrag
Chair: K. Ray Chaudhuri Vice Chair: Per Odin Vice Chair: Annette Schrag


MDS Staff Liaison: Ken Buesing

Steering Committee

Angelo Antonini
Roongroj Bhidayasiri
Cristian Falup-Pecurariu
Beomseok Jeon
Valentina Leta (Junior Member Representative)
Pablo Martinez-Martin
Per Borghammer
Per Odin
Anette Schrag
Alexander Storch
Lars Timmerman
Mayela Rodriguez Violante
Daniel Weintraub

Standing Members

Charles Adler
Paolo Barone
David J Brooks
Richard Brown
Marc Cantillon
Camille Carroll
Miguel Coelho
Haidar Dafsari
Tove Henriksen
Michele Hu
Peter Jenner
Milica Kramberger
Padma Kumar
Mónica Kurtis
Simon Lewis
Kelly Lyons
Davide Martino
Mario Masellis
Hideki Mochizuki 
James F. Morley
Melissa Nirenberg
Javier Pagonabarraga
Jalesh Panicker
Nicola Pavese
Eero Pekkonen
Ron Postuma
Raymond Rosales
Anthony Schapira
Tanya Simuni
Fabrizio Stocchi
Indu Subramanian
Michele Tagliati
Michele Tinazzi
Jon Toledo
Yoshio Tsuboi
Richard Walker


Trainee Subgroup

Current Members

Anna Sauerbier: Chair
Steering Group: Lisa Klingelhoefer, Nataliya Titova

Rebecca Banerjee
Roberta Biundo
Lana Chahine
Haidar Salimi Dafsari
Stefania Diaconu
Roberto Erro
Temitope Farombi
Sanjay Gangadharan
Onanong Jitkritsadakul
Valentina Leta
Philipp Loehrer
Antonella Macerollo
Flavia Niccolini
Gennaro Pagano
Daniel Van Wamelen

MDS NM-PD-SG DBS Research Subcommittee Chair: Lars Timmermann

Managerial and Coordination

Alexandra Rizos
Anna Sauerbier

MDS Non-Motor PD Study Group members pose for a photo in San Diego, CA, in June 2015.


1. To collect new and novel patient and carer reported information on Non-Motor Symptoms (NMS) of Parkinson’s disease from around the world
2. To develop a MDS version of a new PD non motor symptoms scale
3. To ensure that comprehensive and unified NMS assessments in clinical trials and scientific studies are increasingly used to increase the “real life” value of clinical trials and clinical studies
4. To develop new and novel NMS instruments for use in clinics:

  • PD pain scale (currently in development and validation)
  • Vision scale
  • Sexual dysfunction scale
  • Urinary symptoms scale

5. To set up and start international cross cultural studies, to improve existing tools for NMS (e.g. NMSS and NMSQ)
6. To develop animal models addressing non-motor phenotypes of PD
7. To refine, validate and establish non-motor subtypes of PD and related biomarkers

Ongoing Projects

A. The NM-PD study group will aim to complete and publish 3 key studies adopted from the work of the international Parkinson's Disease Non-Motor Group (PDNMG). These are:

  • The EuroInf study: Multicentre, European study comparing key motor, non-motor and quality of life effects of advanced conventional therapies apomorphine infusion, intrajejunal levodopa infusion and subthalamic nucleus deep brain stimulation in PD. Data presented at the MDS congress in Sydney, June 2013.
  • The DAICE-ET study: Multicentre European study of real life comparison of immediate release, long-acting and transdermal dopamine agonists and tolerability in elderly patients with a focus on impulse control disorders. Data presented at the MDS Congress in Sydney, June 2013.
  • EURO-DAWS study: Multi-centre European prospective survey of range, nature and frequency of dopamine agonist withdrawal syndrome in Parkinson’s disease.
  • The definition, characterization and frequency of non-motor sub-types of PD and possible biomarkers exploration.
    The development, and clinical validation of the MDS PD non-motor symptoms scale.

B: Current work packages include:

  • WP 1: Non-motor subtypes and biomarkers
  • WP 2: Development of the MDS- NMS scale
  • WP 3: Animal models
  • WP 4: DBS and non-motor effects in PD
  • WP 5: Studies addressing fatigue and sleepiness in PD

C: Membership information, information on participating in ongoing studies/projects, meetings of NM-PD could be obtained by e-mailing the managers: and

Content to come 


We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice